The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-27
DOI
10.1038/srep35770
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging targeted therapies in non-small cell lung cancer
- (2016) Nabin Khanal et al. Expert Review of Anticancer Therapy
- Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity
- (2015) Vanesa Stojanovska et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
- (2015) Roland Morley et al. PLoS One
- Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
- (2015) Sacha Rothschild Cancers
- Novel drugs against non-small-cell lung cancer
- (2014) Robert Pirker CURRENT OPINION IN ONCOLOGY
- c-MET Inhibitors in the Treatment of Lung Cancer
- (2014) Joanna Goździk-Spychalska et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Protein kinase inhibitors to treat non-small-cell lung cancer
- (2014) Gabriele Minuti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)
- (2014) H.A. Wakelee et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)
- (2014) F.R. Hirsch et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
- (2014) Baoping Guo et al. PLoS One
- MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
- (2014) Anastasios Dimou et al. PLoS One
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
- (2014) Elizabeth Smyth et al. OncoTargets and Therapy
- Novel agents in development for advanced non-small cell lung cancer
- (2014) Thomas E. Stinchcombe Therapeutic Advances in Medical Oncology
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lung Cancer: Epidemiology, Etiology, and Prevention
- (2011) Charles S. Dela Cruz et al. CLINICS IN CHEST MEDICINE
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
- (2011) Neelesh Sharma et al. Therapeutic Advances in Medical Oncology
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
- (2010) Alex Chang LUNG CANCER
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now